Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT05722275 Recruiting - Gastric Cancer Clinical Trials

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Start date: January 1, 2023
Phase:
Study type: Observational

Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.

NCT ID: NCT05721963 Recruiting - Cholangiocarcinoma Clinical Trials

Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients

Start date: February 1, 2023
Phase:
Study type: Observational

This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the accuracy of proteomics approaches on resected lymph node samples in evaluating lymph node metastasis status in cholangiocarcinoma patients.

NCT ID: NCT05717166 Recruiting - Metastatic Tumor Clinical Trials

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

SABR-SYNC
Start date: October 6, 2023
Phase: Phase 3
Study type: Interventional

This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease. Patients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10).

NCT ID: NCT05714475 Recruiting - Colorectal Cancer Clinical Trials

Pancreas Resection for Colorectal Metastasis: Retrospective Study

Start date: January 1, 2023
Phase:
Study type: Observational

The aim of this study is to collect data from different centres to obtain a larger case series and enable a better definition of the outcomes after pancreatic metastasectomy from primary colorectal cancer. To evaluate the possible benefits of surgery, we intend to retrospectively analyze the outcome of patients in whom pancreatic metastases have been surgically treated. Primary objective; 1. To evaluate feasibility and safety of pancreas resection in metastatic colorectal cancer 2. To evaluate oncological outcome at six months from surgical procedure Secondary objective: 1. To evaluate oncological outcome at 12 months from surgical procedure

NCT ID: NCT05703269 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

HYPOGRYPHE
Start date: July 11, 2023
Phase: N/A
Study type: Interventional

This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also being treated with immunotherapy, specifically immune checkpoint inhibitor (ICI) therapy. This study will compare the usual care treatment of single fraction stereotactic radiosurgery (SSRS) given on one day versus fractionated stereotactic radiosurgery (FSRS), which is a lower dose of radiation given over a few days to determine if FSRS is better or worse at reducing side effects than usual care treatment.

NCT ID: NCT05700721 Recruiting - Brain Metastases Clinical Trials

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Start date: June 2, 2023
Phase: Phase 2
Study type: Interventional

To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.

NCT ID: NCT05692635 Recruiting - Brain Metastases Clinical Trials

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Start date: August 30, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.

NCT ID: NCT05692037 Recruiting - Clinical trials for Unresectable Colorectal Liver Metastases

Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases

NRT-uCRLM
Start date: December 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases

NCT ID: NCT05689619 Recruiting - Breast Cancer Clinical Trials

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

SILMET
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).

NCT ID: NCT05681195 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Start date: April 25, 2024
Phase: Phase 2
Study type: Interventional

This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central nervous system lymphoma (PCNSL) or isolated central nervous system relapse of B cell lymphoma (SCNSL). Assessments include how well people respond to this treatment, whether their disease gets better or worse, and their survival. Safety of this treatment and its side effects also will be assessed.